Q-omics provides the consensus-scored C6orf52 profile across patient tissues and cancer cell-line models. C6orf52 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, C6orf52 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C6orf52 RNA expression shows 15,988 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, KIRC, and ACC as cancer lineages where C6orf52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C6orf52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C6orf52 survival associations across molecular data types. C6orf52 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C6orf52 RNA expression–survival associations across cancer types. High C6orf52 expression shows unfavorable associations in ACC, KICH, MESO, LIHC and SARC, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for C6orf52 RNA expression.
This table summarizes C6orf52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for C6orf52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C6orf52 shows lower tumor expression in KIRC, KICH, THCA and KIRP and higher tumor expression in UCEC and LIHC. The KIRC box plot shows higher C6orf52 RNA expression in normal versus tumor tissue (log2 FC = −1.268, t-test p < 0.001).
This table shows molecular features associated with C6orf52 in patient tissues and cancer cell lines. In patient samples, C6orf52 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C6orf52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
